Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
Recruiting · NCT07369596 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Malaya
View the official record on ClinicalTrials.gov →Interventions studied
Overall survivalProgression free survival
What this trial is about
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Who can take part
Age range
65 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥65 years
- Histologically confirmed stage IV NSCLC
- Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
- Treated with at least ONE cycle of first-line chemotherapy
Exclusion criteria
- Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
- Incomplete survival data
Where it is running
4 locations listed.
- Queen Mary Hospital, The University of Hong Kong - Hong Kong, Hong Kong
- Universiti Malaya Medical Centre - Kuala Lumpur, Malaysia
- Hospital Tengku Ampuan Afzan - Kuantan, Pahang, Malaysia
- Hospital Wanita dan Kanak-Kanak Sabah - Kota Kinabalu, Sabah, Malaysia